Patents by Inventor Yasutaka Hoashi

Yasutaka Hoashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20240360080
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: November 27, 2023
    Publication date: October 31, 2024
    Inventors: Yasushi HATTORI, Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO
  • HETEROCYCLIC COMPOUND
    Publication number: 20240317765
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: April 8, 2024
    Publication date: September 26, 2024
    Inventors: Yasushi HATTORI, Marilena PIRA, Yoshiteru ITO, Kohei TAKEUCHI, Eiji KIMURA, Norihito TOKUNAGA, Shuhei IKEDA, Martin Alexander PAWLICZEK, Noriyuki TEZUKA, Yasutaka HOASHI, Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE
  • Heterocyclic compound
    Patent number: 12091410
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: September 17, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Yasutaka Hoashi, Yasushi Hattori, Norihito Tokunaga, Tsuneo Oda, Tohru Miyazaki, Dilhumar Uyghur, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto, Koichiro Fukuda, Yasuhisa Kohara, Rei Okamoto, Taiichi Ohra, Naoki Miyamoto, Yoshito Terao, Masanori Kawasaki
  • Heterocyclic compound and application thereof
    Patent number: 12077522
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: September 3, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Koichiro Fukuda, Hiromichi Sugimoto, Kentaro Rikimaru, Yoshihiro Banno, Takahiro Matsumoto, Norihito Tokunaga, Yoshihide Tomata, Yuji Ishichi, Shogo Marui, Tsuneo Oda, Tohru Miyazaki, Yasutaka Hoashi, Yasushi Hattori, Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike
  • Heterocyclic compound
    Patent number: 12071434
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: August 27, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike, Yasutaka Hoashi, Yasushi Hattori, Norihito Tokunaga, Tsuneo Oda, Tohru Miyazaki, Dilhumar Uyghur, Yoshiteru Ito, Kohei Takeuchi, Keisuke Imamura, Takahiro Sugimoto, Koichiro Fukuda, Yasuhisa Kohara, Rei Okamoto, Taiichi Ohra, Naoki Miyamoto, Jun Chiba, Yoshito Terao, Masanori Kawasaki
  • HETEROCYCLIC COMPOUND
    Publication number: 20240174677
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: October 30, 2023
    Publication date: May 30, 2024
    Inventors: Yasushi HATTORI, Marilena PIRA, Yoshiteru ITO, Kohei TAKEUCHI, Eiji KIMURA, Norihito TOKUNAGA, Shuhei IKEDA, Martin Alexander PAWLICZEK, Noriyuki TEZUKA, Yasutaka HOASHI, Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE
  • Cationic lipids
    Patent number: 11993570
    Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: May 28, 2024
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Satoru Matsumoto, Yoshimasa Omori, Masahiro Mineno, Yasutaka Hoashi
  • Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists
    Patent number: 11987586
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: October 30, 2023
    Date of Patent: May 21, 2024
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi Hattori, Marilena Pira, Yoshiteru Ito, Kohei Takeuchi, Eiji Kimura, Norihito Tokunaga, Shuhei Ikeda, Martin Alexander Pawliczek, Noriyuki Tezuka, Yasutaka Hoashi, Yuhei Miyanohana, Yuichi Kajita, Tatsuki Koike
  • CATIONIC LIPIDS
    Publication number: 20230257338
    Abstract: The present invention provides a technique that enables introduction of active ingredients, in particular, nucleic acids, into cells with superior efficiency; and cationic lipids, etc., for use in the technique. The compound or a salt thereof according to the present invention is a compound represented by formula (I) or a salt thereof. In formula (I), n represents an integer of 2 to 5, R represents a linear C1-5 alkyl group, a linear C7-11 alkenyl group, or a linear C11 alkadienyl group, and wavy lines each independently represent a cis-bond or a trans-bond.
    Type: Application
    Filed: August 31, 2022
    Publication date: August 17, 2023
    Inventors: Satoru Matsumoto, Yoshimasa Omori, Masahiro Mineno, Yasutaka Hoashi
  • Heterocyclic compound and use thereof
    Patent number: 11655241
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: May 23, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo Oda, Yoshiteru Ito, Tohru Miyazaki, Kohei Takeuchi, Norihito Tokunaga, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura, Yuichi Kajita, Yuhei Miyanohana, Takahiro Sugimoto, Tatsuki Koike, Dilhumar Uyghur
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20230063805
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 22, 2022
    Publication date: March 2, 2023
    Inventors: Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE, Kohei TAKEUCHI, Yoshiteru ITO, Norihito TOKUNAGA, Takahiro SUGIMOTO, Tohru MIYAZAKI, Tsuneo ODA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20230040770
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: January 30, 2020
    Publication date: February 9, 2023
    Inventors: Yasushi HATTORI, Yuhei MIYANOHANA, Tatsuki KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO
  • HETEROCYCLIC COMPOUND
    Publication number: 20230042358
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 9, 2023
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Jun CHIBA, Yoshito TERAO, Masanori KAWASAKI
  • HETEROCYCLIC COMPOUND
    Publication number: 20230037557
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: November 26, 2020
    Publication date: February 9, 2023
    Inventors: Yoshiteru ITO, Yuhei MIYANOHANA, Yuichi KAJITA, Yasutaka HOASHI, Yasushi HATTORI, Tatsuki KOIKE, Norihito TOKUNAGA, Eiji KIMURA, Alexander Martin PAWLICZEK, Marilena PIRA, Javier MIGUELEZ-RAMOS
  • Heterocyclic compound and use thereof
    Patent number: 11440883
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: September 13, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi Kajita, Yuhei Miyanohana, Tatsuki Koike, Kohei Takeuchi, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tohru Miyazaki, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • Heterocyclic compound and application thereof
    Patent number: 11319286
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: May 3, 2022
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko Fujimoto, Kentaro Rikimaru, Koichiro Fukuda, Hiromichi Sugimoto, Takahiro Matsumoto, Yuichi Kajita, Satoshi Mikami, Yuhei Miyanohana, Tatsuki Koike, Masaki Daini, Masaki Ogino, Kohei Takeuchi, Tohru Miyazaki, Yoshiteru Ito, Norihito Tokunaga, Takahiro Sugimoto, Tsuneo Oda, Yasutaka Hoashi, Yasushi Hattori, Keisuke Imamura
  • HETEROCYCLIC COMPOUND
    Publication number: 20220017514
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: December 11, 2019
    Publication date: January 20, 2022
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE, Yasutaka HOASHI, Yasushi HATTORI, Norihito TOKUNAGA, Tsuneo ODA, Tohru MIYAZAKI, Dilhumar UYGHUR, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO, Koichiro FUKUDA, Yasuhisa KOHARA, Rei OKAMOTO, Taiichi OHRA, Naoki MIYAMOTO, Yoshito TERAO, Masanori KAWASAKI
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20210276949
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: April 23, 2021
    Publication date: September 9, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Yasushi HATTORI, Yuhei MIYANOHANA, Yuichi KAJITA, Tatsuki KOIKE, Yasutaka HOASHI, Norihito TOKUNAGA, Alexander Martin PAWLICZEK, Tsuneo ODA, Tohru MIYAZAKI, Yoshiteru ITO, Kohei TAKEUCHI, Keisuke IMAMURA, Takahiro SUGIMOTO
  • HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
    Publication number: 20210269420
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 27, 2019
    Publication date: September 2, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tatsuhiko FUJIMOTO, Koichiro FUKUDA, Hiromichi SUGIMOTO, Kentaro RIKIMARU, Yoshihiro BANNO, Takahiro MATSUMOTO, Norihito TOKUNAGA, Yoshihide TOMATA, Yuji ISHICHI, Shogo MARUI, Tsuneo ODA, Tohru MIYAZAKI, Yasutaka HOASHI, Yasushi HATTORI, Yuichi KAJITA, Yuhei MIYANOHANA, Tatsuki KOIKE
  • HETEROCYCLIC COMPOUND AND USE THEREOF
    Publication number: 20210198240
    Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.
    Type: Application
    Filed: June 27, 2019
    Publication date: July 1, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Tsuneo ODA, Yoshiteru ITO, Tohru MIYAZAKI, Kohei TAKEUCHI, Norihito TOKUNAGA, Yasutaka HOASHI, Yasushi HATTORI, Keisuke IMAMURA, Yuichi KAJITA, Yuhei MIYANOHANA, Takahiro SUGIMOTO, Tatsuki KOIKE, Dilhumar UYGHUR